A 14-year-old patient with acquired very severe aplastic anemia (VSAA) underwent bone marrow transplantation (BMT) from his HLA-identical brother. Preparative therapy was cyclophosphamide (CY) 200 mg/kg over 4 days. GVHD prophylaxis was with cyclosporin A (CsA) for a year. After an 8 year follow-up during which the patient was well with normal blood counts, graft failure occurred. At this time marrow chimerism studies demonstrated that 85% of hemopoiesis was of recipient origin. The patient was re-engrafted from the same donor after conditioning with CY 200 mg/kg over 4 days plus rabbit antithymocyte globulin (ATG) 3.5 mg/kg/day for 3 days. After 140 days follow-up he has a normal blood count. The possible causes of the graft failure are discussed. This case demonstrates that, although rarely, very late graft failure may occur after BMT for AA and highlights the need for long-term monitoring even in apparently successfully transplanted patients.
BMT from an HLA-identical sibling is the treatment of choice for young patients with acquired severe aplastic anemia (SAA). Some series report a survival rate of 92%. 1 Relapses occur in 5-10% of cases 2, 3 mostly within the second year after BMT. 1, 4 We report an acquired VSAA patient who was initially transplanted from his HLA-identical brother. This patient had sustained engraftment but experienced late graft failure 8 years after the first BMT and underwent a second BMT from the same donor.
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Case report
A 14-year-old Italian boy presented with fatigue and bruising in January 1990. His past personal and familial history were unremarkable. Initial investigations showed: WBC 1.8 ϫ 10 9 /l, PMN 0.19 ϫ 10 9 /l, Hb 8.1 g/dl, reticulocytes 0.1%, platelets (Plts) 5 ϫ 10 9 /l. Bone marrow aspirate was hypocellular with no blasts or dysplastic cells. The trephine biopsy showed haemopoietic cellularity of 5%. Bone marrow karyotype was normal (46 XY) in all cells analysed. The diepoxybutane test (DEB) was normal and Ham's test was negative with both patient and normal donor serum.
Virological studies (HAV, HBV, HSV, CMV, EBV), renal and liver function tests were all normal. A diagnosis of idiopatic very SAA was made.
In February 1990 the patient was conditioned for BMT with cyclophoshamide (CY) 200 mg/kg over 4 days. One day later he received bone marrow from his HLA-identical brother containing 2.7 ϫ 10 8 nucleated cells/kg recipient's body weight. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporin A (CsA) 3 mg/kg i.v. from day Ϫ1 to day ϩ21 and then 12 mg/kg/day orally up to day 365. By day ϩ20, the WBC had increased to Ͼ1 ϫ10 9 /l with 50% of PMNs. Plts increased to Ͼ50 ϫ 10 9 /l from day ϩ20. Overall, the patient received six Plt (four before and two after the transplant) and 10 packed red cell (PRC) transfusions (six before and four after the transplant), all from different donors. The last Plt and PRC transfusions were given on days ϩ15 and ϩ19, respectively. The post-BMT course was not complicated by acute GVHD or by infections. Twenty days after the transplant the patient was discharged from the hospital.
Complete engraftment was demonstrated on day ϩ88 by short tandem repeat (STR) polymorphisms via PCR-based technology 5 on peripheral blood. The patient remained well with a normal blood count up to February 1998 when, after an upper respiratory tract infection, his Plts dropped to 47 ϫ 10 9 /l. At this time the WBC was 4.1 ϫ 10 9 /l, PMN 71% and Hb 10.3 g/dl. Bone marrow aspirate and trephine biopsy were hypocellular (25%) with no blasts or dysplastic cells. Marrow cytogenetic study was normal in all cells analysed.
Flow cytometric analysis by monoclonal antibodies showed that marrow HLA-DR ϩ cells were 7%, CD3 ϩ 58%, CD4 ϩ 29%, CD8 ϩ 26%, CD56 ϩ 8%, CD19 ϩ 6%. Detection of intracytoplasmic ␥ interferon (IFN) 6 in marrow lymphocytes revealed that 6% of CD4 ϩ and 10% of CD8 ϩ cells were positive for this cytokine. Furthermore, 9% of CD4 ϩ cells expressed intra-cellular ␣TNF which was virtually undetectable in CD8 ϩ cells. These values are higher than those found in normal, age-matched, controls (ranges for ␥IFN:CD4 ϩ = 1-3%; CD8 ϩ = 3-7%. Range for ␣TNF: CD4 ϩ 3-5%). The DEB test was again negative as were virological studies (CMV, EBV, HAV, HBV, HSV, VZV). STR polymorphism on peripheral blood showed haemopoiesis to be 70% recipient and 30% of donor origin.
The patient was started on oral CsA 10 mg/kg/day plus methylprednisolone 1 mg/kg/day to which he failed to respond and 3 months later the Plts dropped to 18 ϫ 10 9 /l, WBC to 3.1 ϫ 10 9 /l, PMN 13% and Hb to 7 g/dl. At this time the bone marrow trephine biopsy showed a cellularity of 10%. LTC-IC were undetectable (normal controls 34-Ͼ100/10 6 cells). STR polymorphisms carried out on committed marrow progenitor cells demonstrated that 85% of the CFU-GM were of recipient origin. A diagnosis of recurrent idiopatic SAA was made.
In June 1998 the patient underwent preparation for second BMT from the same donor with CY 200 mg/kg over 4 days plus rabbit antithymocyte globulin (ATG) 3.5 mg/kg/day for 3 days. Twenty-four hours after the last dose he received bone marrow containing 3 ϫ 10 8 /kg nucleated cells. GVHD prophylaxis was with CsA 3 mg/kg/day i.v. from day Ϫ1 to day ϩ21 and then 12 mg/kg/day orally. Methotrexate 8 mg/m 2 was given on days ϩ1, ϩ3, ϩ6, ϩ11. Hemopoietic reconstitution was rapid. By day ϩ16 the WBC increased to Ͼ1 ϫ 10 9 /l with 55% of PMN, Hb Ͼ9 g/dl became stable 16 days after the transplant. Plts increased to Ͼ50 ϫ 10 9 /l on day ϩ16. The patient required seven Plt (three before and four after the transplant) and six PRC (three before and three after the graft) transfusions, all from different donors. Full engraftment was demonstrated on day ϩ33 by STR polymorphisms on peripheral blood.
At the time of writing, on day ϩ140 from the second BMT, the patient is well, the WBC is 5.5 ϫ 10 9 /l, PMN 63%, Hb 13 g/dl, Plts 264 ϫ 10 9 /l.
Discussion
Graft failure after BMT for acquired SAA is generally reported to occur early after the transplant. In the series published by Storb et al 1 two patients rejected the graft at months ϩ2 and ϩ6. In the European Bone Marrow Transplant Group study 3 the latest re-transplant was done 3 years after the first graft. In a less recent study 4 acquired SAA patients were re-transplanted at a median time of 86 days after the first transplant and the longest interval between the first and the second transplant was 2 years. In the large IBMTR study the latest failure occurred 3 years after BMT. 7 Our patient was well with a normal blood count for 8 years after the first BMT. Thereafter, he had graft failure documented by marrow severe hypocellularity (10%) and the marrow progenitor cell chimerism study which showed haemopoiesis to be mostly (85%) of recipient origin. Reasons for this failure can only be hypothesised. First, the preparative regimen, which included CY alone, was not ablative and therefore it is possible that, after many years, the damaged recipient stem cell pool re-emerged, mediating defective haemopoiesis. Second, the number of infused marrow cells was just below the threshold (3 ϫ 10 8 /kg recipient's body weight) reported as safe for durable engraftment. 8 Nonetheless, the patient maintained adequate haemopoiesis for 8 years as demonstrated by his normal blood count. However, the reduced number of infused cells might have facilitated re-emergence of the recipient stem cell pool. It may also be speculated that the infection which preceded the graft failure in February 1998, or re-exposure to an initial or new toxin played a triggering role, in the light of the suboptimal marrow reserve after BMT. Third, the patient received a relatively high number (10) of pretransplant transfusions, all from different donors. Transfusions may favour rejection since they sensitise the recipient to donor minor histocompatibility antigens. Moreover, it has been reported that multiply transfused patients who are conditioned with CY alone have an increased risk of rejection. 8 On this basis, transfusions might have contributed to the graft failure. Finally, it cannot be excluded that the graft failure resulted from all the above possible causes acting synergistically.
At the time of graft failure there was increased intracytoplasmic expression of ␥IFN in both CD4 ϩ and CD8 ϩ marrow cells and of ␣TNF in CD4 ϩ cells only. These findings are in keeping with others from the literature 9-11 and suggest that local ␥IFN and ␣TNF overproduction might have been involved in stem cell suppression.
Whatever the mechanism responsible for the graft failure, it is of relevance that it was possible to rescue the patient with a second transplant from the same donor. This time the preparative regimen included ATG in addition to CY. This association is reported to produce a synergistic immunosuppressive effect 1 which was desirable in order to reduce the risk of second rejection in this heavily transfused patient. Moreover, in a Seattle study 5 this regimen resulted in a very low graft rejection rate in multiply transfused SAA patients undergoing second BMT.
Our case demonstrates that late graft failure may occur in patients transplanted for AA and stresses the need for long-term monitoring of patients who have been transplanted successfully. Monitoring should also include interim chimerism studies. If the same donor is available, a second BMT might allow suitable salvage. 2, 4 
